Immunotherapy use outside clinical trial populations: never say never?

BACKGROUND: Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, are now widely used across multiple cancer types. However, due to their strict inclusion and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rzeniewicz, K., Larkin, J., Menzies, A.M., Turajlic, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246438/
https://www.ncbi.nlm.nih.gov/pubmed/33771665
http://dx.doi.org/10.1016/j.annonc.2021.03.199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246438/
https://www.ncbi.nlm.nih.gov/pubmed/33771665
http://dx.doi.org/10.1016/j.annonc.2021.03.199

Ejemplares similares